NYSE:GSK News 1 December 2025 - 15 December 2025

GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead GSK plc stock (LSE: GSK, NYSE: GSK) is ending 2025 with a rare “cluster” of market-moving catalysts packed into the same two-week window: fresh U.S. regulatory momentum for a new antibiotic, European regulatory backing for multiple respiratory products, and an imminent FDA decision that could reshape GSK’s long-term outlook in severe asthma and nasal polyps. For investors, this isn’t just headline noise. It’s the kind of sequencing—approval decisions, label expansions, and portfolio reinforcement—that can change how analysts

Updated: December 13, 2025 GSK plc (LSE: GSK, NYSE: GSK) is ending the week in the spotlight after a cluster of regulatory updates in Europe and the United States—exactly the kind of “catalyst stacking” that can shift the narrative around a big pharma stock from defensive dividend name to pipeline and launch execution story. Add in an active share buyback program, a clearly mapped dividend calendar, and an incoming CEO transition in early 2026, and GSK stock has plenty for investors to digest heading into year-end. GSK+3Reuters+3Reuters+3 As of the latest available quote, GSK’s U.S.-listed ADR was about $48.81, with